Porcine epidemic diarrhea (PED) caused by porcine epidemic diarrhea virus (PEDV) is widespread in the world . In recent years, the increased virulence of the virus due to viral variations, has caused great economic losses to the pig industry in many countries . It is always worthy to find effective therapeutic methods for PED . As an important class of antivirals, nucleoside drugs which target viral polymerases have been applied in treating human viral infections for half a century . Herein, we evaluated the anti-PEDV potential of three broad-spectrum antiviral nucleoside analogs, remdesivir (RDV), its parent nucleoside (RDV-N) and β-D-N 4 -hydroxycytidine (NHC). Among them, RDV-N was the most active agent in Vero E6 cells with EC 50 of 0.31 μmol/L, and more potent than RDV (EC 50 = 0.74 μmol/L) and NHC (EC 50 = 1.17 μmol/L). The activity of RDV-N was further confirmed using an indirect immuno-fluorescence assay . Moreover, RDV-N exhibited a good safety profile in cells and in mice . The high sequence similarity of the polymerase functional domains of PEDV with other five porcine coronaviruses indicated a broader antiviral spectrum for the three compounds . Generally, RDV-N is a promising broad-spectrum antiviral nucleoside, and it would be worthy to make some structural modifications to increase its oral bioavailability.
Index: Antiviral activity, Nucleoside analog, Porcine epidemic diarrhea virus (PEDV), RNA dependent RNA polymerase (RdRp)